It may seem odd, as unprecedented public/private sector R&D alliances work to discover and develop therapies to counter COVID-19, that some are trying to punish the companies trying to get us out of this mess. For example, House “Progressive” leaders unveiled the “three protections” they will try to insert in the next Congressional aid package, beginning with this: “NO EXCLUSIVITY: Pharmaceutical manufacturers should not be granted exclusivity for any COVID-19 vaccine, drug, or other therapeutic-whether it has been developed with U.S. taxpayer dollars and publicly funded, or not.” Consider the last phrase. They would take away rights to technologies developed entirely with private funding without evidence of any public need for doing so.
Patent
- Enablement
- Fee Shifting
- Litigation
- Defensive Publications: A Cost-Effective Tool to Supplement Your Patent Strategy
- A Stylized Word Mark in One Country May Be Too Simple and Common in Another
- Other Barks & Bites for Friday, May 22: Copyright Office Issues Section 512 Safe Harbor Report, CAFC Denies Review of PTAB Institution Decision and Director Iancu on Possible Filing Deadline Extension
- CAFC Finds Claim for Delivery Notification System Abstract as Directed to a Longstanding Commercial Practice
- PTAB Institution Data Analysis Proves That Reforms Have Failed
Recent Posts
- Defensive Publications: A Cost-Effective Tool to Supplement Your Patent Strategy
- A Stylized Word Mark in One Country May Be Too Simple and Common in Another
- Other Barks & Bites for Friday, May 22: Copyright Office Issues Section 512 Safe Harbor Report, CAFC Denies Review of PTAB Institution Decision and Director Iancu on Possible Filing Deadline Extension
- CAFC Finds Claim for Delivery Notification System Abstract as Directed to a Longstanding Commercial Practice
- PTAB Institution Data Analysis Proves That Reforms Have Failed